Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005073 · ClinicalTrials.gov registry record · Phase 3
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 544
- Enrollment target
NCT00005073: Clinical Trial Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00005073 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 544 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005073, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 544 participants
- Enrollment target
Study Summary
RATIONALE: Zoledronate may be able to prevent bone metastases caused by prostate cancer. It is not yet known if zoledronate is effective in preventing the spread of prostate cancer to the bones. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate plus standard therapy in preventing bone metastases in patients who have recurrent prostate cancer that is not causing symptoms.
Interventions
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 544 participants |
| Start Date | 1999-09 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Why NCT00005073 stopped before completion
NCT00005073 is an interventional study that assigns participants to a tested intervention. The registered 544 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 1 intervention - of which zoledronic acid is the first listed.
NCT00005073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005073 about?
NCT00005073 is a clinical study titled "Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms". RATIONALE: Zoledronate may be able to prevent bone metastases caused by prostate cancer. It is not yet known if zoledronate is effective in preventing the spread of prostate cancer to the bones. PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate plus standard therapy ...
What is the current status of trial NCT00005073?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 544 participants. The study started on 1999-09. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00005073?
The interventions under investigation include: zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00005073?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005073's enrollment target sits among peer trials
544 691st of 2000 higher than 1,307 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127761 · 544 participants
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- NCT04378790 · 544 participants · Phase 3
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
- NCT06118502 · 544 participants · NA
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
- NCT06170437 · 544 participants · NA
Smoke-free Home Study in Subsidized Housing
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia